Last Updated: November 17, 2026

Midostaurin - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for midostaurin and what is the scope of freedom to operate?

Midostaurin is the generic ingredient in two branded drugs marketed by Dr Reddys, Lupin, Teva Pharms, and Novartis, and is included in four NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for midostaurin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Hospitalier Universitaire de NiceNA
Richard Stone, MDPHASE1
Syndax PharmaceuticalsPHASE1

See all midostaurin clinical trials

Generic filers with tentative approvals for MIDOSTAURIN
Applicant Application No. Strength Dosage Form
⤷  Start Trial⤷  Start Trial25MGCAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for midostaurin
Paragraph IV (Patent) Challenges for MIDOSTAURIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RYDAPT Capsules midostaurin 25 mg 207997 4 2021-04-28

US Patents and Regulatory Information for midostaurin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis RYDAPT midostaurin CAPSULE;ORAL 207997-001 Apr 28, 2017 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Dr Reddys MIDOSTAURIN midostaurin CAPSULE;ORAL 215921-001 Jun 28, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novartis RYDAPT midostaurin CAPSULE;ORAL 207997-001 Apr 28, 2017 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms MIDOSTAURIN midostaurin CAPSULE;ORAL 216076-001 Apr 29, 2024 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lupin MIDOSTAURIN midostaurin CAPSULE;ORAL 216015-001 May 10, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for midostaurin

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Ltd Rydapt midostaurin EMEA/H/C/004095Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). Authorised no no yes 2017-09-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for midostaurin

Country Patent Number Title Estimated Expiration
Austria 335490 ⤷  Start Trial
Australia 2006249245 ⤷  Start Trial
Brazil 0213739 ⤷  Start Trial
Brazil PI0213739 uso de derivados de estaurosporina como inibidores de atividade de receptores flt3 de tirosina cinase no tratamento de leucemia mielóide aguda e síndromes mielodisplásicas de alto risco ⤷  Start Trial
Canada 2462657 DERIVES DE STAUROSPORINE INHIBITEURS DE L'ACTIVITE TYROSINE KINASE DU RECEPTEUR FLT3 (STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY) ⤷  Start Trial
China 101703509 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for midostaurin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1638574 CR 2018 00001 Denmark ⤷  Start Trial PRODUCT NAME: MIDOSTAURIN ELLER ET SALT DERAF; REG. NO/DATE: EU/1/17/1218 20170920
1638574 659 Finland ⤷  Start Trial
1638574 2017C/067 Belgium ⤷  Start Trial PRODUCT NAME: MIDOSTAURIN OU UN DE SES SELS (RYDAPT); AUTHORISATION NUMBER AND DATE: EU/1/17/1218 20170920
1638574 300917 Netherlands ⤷  Start Trial PRODUCT NAME: MIDOSTAURINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1218 20170920
1638574 6/2018 Austria ⤷  Start Trial PRODUCT NAME: MIDOSTAURIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1218 20170920
1638574 132018000000001 Italy ⤷  Start Trial PRODUCT NAME: MIDOSTAURINA O UN SUO SALE(RYDAPT ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1218, 20170920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Midostaurin Market Dynamics, Revenue Trajectory, Patent Position, and Competitive Outlook

Last updated: November 11, 2026

Midostaurin, marketed by Novartis as Rydapt, is a targeted kinase inhibitor with two approved commercial uses: newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and advanced systemic mastocytosis. Global sales have remained broadly stable at roughly $0.5 billion annually, supported by a specialized AML population and continued use in advanced systemic mastocytosis. The principal commercial risks are competition from gilteritinib and quizartinib in FLT3-mutated AML, avapritinib in systemic mastocytosis, and eventual generic entry after regulatory and patent barriers weaken.

What is midostaurin used for and how does Rydapt generate revenue?

Midostaurin is an oral multikinase inhibitor that targets FLT3, KIT, and other kinases. Rydapt is approved in the United States for:

  • Newly diagnosed AML in adults whose blasts have a FLT3 mutation, used with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy.
  • Adults with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.

The AML indication is commercially important because it places Rydapt in the front-line treatment pathway. The drug is used with chemotherapy rather than as a stand-alone regimen, which limits total treatment duration but anchors use at diagnosis.

The systemic mastocytosis indication has a smaller patient population and a more chronic treatment pattern. Patients with advanced disease may receive treatment for longer periods, increasing revenue per patient. That benefit is constrained by competition from more selective KIT inhibitors.

Metric Assessment
Active ingredient Midostaurin
Brand Rydapt
Originator Novartis
FDA approval April 28, 2017 for FLT3-mutated AML; September 1, 2017 for advanced systemic mastocytosis
Drug class Oral multikinase inhibitor
Main commercial markets United States, Europe, Japan and other major oncology markets
Primary AML biomarker FLT3 mutation
Main competing AML drugs Gilteritinib, quizartinib and salvage chemotherapy
Main systemic mastocytosis competitor Avapritinib
Product type Small molecule; biosimilar substitution does not apply

The FDA approved Rydapt with companion diagnostic testing for FLT3 mutation status. Novartis relies on a narrow, biomarker-defined AML population rather than broad AML use. The commercial model therefore depends on testing rates, treatment guidelines, diagnosis volumes, and continued physician adoption.

How have midostaurin sales changed over time?

Rydapt sales have followed a mature-product pattern, with annual revenue generally near $0.5 billion rather than showing the rapid growth associated with a newly launched oncology medicine.

Reported Novartis product sales were approximately:

Year Rydapt sales Market interpretation
2020 About $0.52 billion Established AML and systemic mastocytosis demand
2021 About $0.53 billion Stable use despite competitive entry
2022 About $0.55 billion Resilient demand in both indications
2023 About $0.55 billion Mature, broadly flat revenue profile
2024 Approximately $0.5 billion range Continued commercial durability, with competition limiting growth

Figures are rounded and reflect Novartis reported product sales, not publicly disclosed revenue by indication. Novartis reports Rydapt as a product rather than publishing separate revenue for AML and systemic mastocytosis in its standard financial statements (Novartis, 2021, 2022, 2023, 2024).

The financial trajectory has three defining characteristics:

  1. AML provides volume and guideline-driven demand.
  2. Systemic mastocytosis provides a smaller but potentially longer-duration treatment base.
  3. Competitive products limit price and volume expansion.

Rydapt is no longer a high-growth asset. Its value is closer to that of a durable specialty oncology franchise with moderate revenue concentration and a relatively defensible clinical position.

What factors are supporting Rydapt revenue?

How does the AML indication support demand?

The RATIFY trial established the clinical basis for adding midostaurin to standard induction and consolidation chemotherapy in newly diagnosed FLT3-mutated AML. The trial showed improved overall survival compared with chemotherapy alone, supporting incorporation into treatment guidelines and regulatory approvals (Stone et al., 2017).

Demand benefits from several factors:

  • FLT3 mutations occur in roughly one-quarter to one-third of AML cases.
  • Patients are routinely tested for FLT3 at diagnosis.
  • Rydapt is embedded in a front-line regimen rather than reserved only for relapsed disease.
  • The treatment has long-standing physician familiarity.
  • The product is available across multiple major oncology markets.

The main limitation is that Rydapt is not used in all AML patients. It is restricted to FLT3-mutated disease and is most relevant to patients fit for intensive chemotherapy. Older or medically frail patients may receive lower-intensity regimens, reducing the addressable population.

How does systemic mastocytosis support revenue?

The systemic mastocytosis indication gives Rydapt access to a rare-disease population with high unmet need. Advanced systemic mastocytosis is associated with organ damage, aggressive disease biology and poor prognosis. Midostaurin demonstrated activity across advanced systemic mastocytosis subtypes and became an important treatment option after approval (Gotlib et al., 2016).

This indication has favorable revenue characteristics:

  • Disease severity can support specialty-drug pricing.
  • Treatment may continue longer than a defined AML chemotherapy course.
  • Diagnosis often occurs through specialist hematology centers.
  • Patient management is concentrated, which can support targeted commercial infrastructure.

The main pressure is avapritinib, a more selective KIT D816V inhibitor with approvals spanning advanced and indolent systemic mastocytosis. Avapritinib has a stronger mechanistic fit for KIT-driven disease and can compete directly for advanced systemic mastocytosis patients.

How does Rydapt compare with competing FLT3 inhibitors?

Rydapt remains strongest in newly diagnosed FLT3-mutated AML treated with intensive chemotherapy. Its position is less secure in relapsed or refractory disease, where other FLT3 inhibitors have stronger labels or more direct clinical use.

Drug Company Primary AML position Competitive effect on Rydapt
Rydapt, midostaurin Novartis Newly diagnosed FLT3-mutated AML with chemotherapy Established front-line standard
Xospata, gilteritinib Astellas Relapsed or refractory FLT3-mutated AML Limits Rydapt in later-line use
Vanflyta, quizartinib Daiichi Sankyo Newly diagnosed FLT3-ITD-positive AML with chemotherapy Direct front-line competitor
Ayvakit, avapritinib Bristol Myers Squibb Advanced and indolent systemic mastocytosis Direct systemic mastocytosis competitor

Quizartinib is the most important newer AML competitor because it entered the same general front-line FLT3-mutated AML setting. The FDA approved quizartinib in 2023 for adults with newly diagnosed AML that is FLT3-ITD positive, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, followed by maintenance monotherapy in eligible patients (FDA, 2023).

The competitive distinction is clinically relevant:

  • Midostaurin covers FLT3 mutations broadly within its approved setting.
  • Quizartinib focuses on FLT3-ITD-positive disease.
  • Gilteritinib is primarily positioned in relapsed or refractory FLT3-mutated AML.
  • Treatment selection depends on mutation subtype, chemotherapy fitness, transplant strategy, institutional protocols and reimbursement.

The arrival of quizartinib creates the clearest risk to Rydapt’s AML growth. It does not automatically eliminate Rydapt demand because the products have different data packages, labels, mutation coverage and physician adoption patterns.

What is the FDA regulatory status and exclusivity position of Rydapt?

Rydapt has full FDA approval in two orphan oncology indications. The FDA approval history is:

Date Regulatory event
April 28, 2017 Approval for newly diagnosed FLT3-mutated AML with chemotherapy
September 1, 2017 Approval for advanced systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia
2023 Continued FDA-approved use as a front-line AML option while quizartinib entered the market

The seven-year orphan-drug exclusivity periods attached to the 2017 approvals would generally have ended in 2024, subject to indication-specific regulatory treatment and any applicable pediatric extension. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity period, but it does not block all competing products.

Rydapt is a small molecule, so it does not receive the 12-year biologic exclusivity framework or face biosimilar competition. Future competition would come through abbreviated new drug applications for generic midostaurin, subject to patent, regulatory and formulation barriers.

What patents protect midostaurin and when could generic entry occur?

Rydapt protection has several potential layers:

  • The active ingredient and chemical composition.
  • Pharmaceutical formulations and oral dosage forms.
  • Methods of treating FLT3-mutated AML.
  • Methods of treating advanced systemic mastocytosis.
  • Regulatory exclusivity linked to orphan indications.
  • Possible pediatric exclusivity or patent-term adjustment.

The original chemical matter is older than the 2017 FDA approvals. Commercial protection therefore depends more heavily on later formulation, dosing and method-of-use rights than on the original compound patent.

The U.S. Orange Book should be used to identify live listed patents and their exact expiration dates. Public patent records associate Rydapt with later-issued midostaurin patents that can extend protection beyond the original chemical patent, with certain rights reported into the late 2020s or around 2030 depending on the patent, jurisdiction and applicable adjustments (FDA, 2024; USPTO, 2024).

A practical entry framework is:

Period Generic-entry risk
Before 2024 Limited by orphan exclusivity and listed patent rights
2024 onward Orphan exclusivity barrier begins to fall away
Late 2020s Risk increases as later patents approach expiry or are challenged
Around 2030 Potentially material U.S. generic exposure, subject to patent litigation and FDA approval timing

No biosimilar risk exists because midostaurin is not a biologic. Generic risk is more likely to emerge through paragraph IV patent challenges than through a biosimilar pathway.

Which companies are challenging Rydapt exclusivity?

Publicly disclosed commercial activity around Rydapt has centered more on competitive product launches than on a widely documented, mature generic litigation campaign. Generic manufacturers could challenge listed patents through paragraph IV certifications, but the business case depends on:

  • The remaining patent term.
  • The ability to demonstrate bioequivalence for the capsule formulation.
  • The commercial value of the AML and systemic mastocytosis indications.
  • The cost of patent litigation.
  • The potential for a first-filer 180-day generic exclusivity period.
  • Whether a generic applicant can carve out patented methods of use.

A generic applicant may seek approval for non-patented indications while using a skinny label to exclude protected methods. That strategy could be difficult for Rydapt if the principal commercial value is concentrated in the same indications covered by method-of-use patents.

No confirmed Rydapt settlement terms with a major generic challenger are reflected in the cited public sources. This limits the ability to assign a specific authorized-generic launch date or settlement-based entry date.

How strong is the midostaurin patent estate?

Rydapt has a moderate commercial patent position rather than a classic long-life composition-of-matter estate.

Strengths include:

  • Multiple indications with separate regulatory histories.
  • Specialized oncology use that makes clinical substitution more difficult than simple tablet substitution.
  • Potential method-of-use protection.
  • A technically defined patient population requiring diagnostic confirmation.
  • High switching costs in established AML treatment pathways.

Weaknesses include:

  • The underlying molecule is not new.
  • The FDA orphan-exclusivity period has ended.
  • Several competing FLT3 inhibitors are already approved.
  • Generic applicants may challenge formulation or method patents.
  • The product has no biologic exclusivity.
  • AML treatment is increasingly segmented by FLT3 subtype and treatment fitness.

The commercial durability of Rydapt therefore depends on patent enforcement, physician familiarity, guideline persistence and the ability to retain share against quizartinib and gilteritinib.

What litigation and settlement risks affect Rydapt?

The principal legal risks are likely to involve:

  1. Paragraph IV challenges to listed U.S. patents.
  2. Declaratory-judgment actions over method-of-use or formulation claims.
  3. Patent-term and pediatric-extension disputes.
  4. Carve-out labeling disputes.
  5. Competition between Rydapt and newer targeted AML products.

A generic litigation event could accelerate valuation pressure even before commercial launch. Investors typically revalue mature oncology products when a credible first filer identifies a viable path to market, especially if the product has a concentrated revenue base and limited post-launch growth.

No confirmed settlement agreement is identified in the cited sources that establishes an authorized generic or a fixed Rydapt entry date. Patent litigation status should therefore be treated as a live diligence item rather than a resolved commercial event.

What is the geographic coverage and international risk?

Novartis sells Rydapt in major oncology markets, including the United States, Europe and Japan. International revenue is affected by:

  • National reimbursement decisions.
  • Health technology assessment outcomes.
  • Regional testing rates for FLT3 and KIT mutations.
  • Reference pricing.
  • Local patent terms.
  • Generic approval timing.
  • Differences in AML treatment guidelines.

The United States remains strategically important because of higher oncology pricing and a large concentration of specialty care. Europe provides broad market access but generally carries greater price pressure and country-level reimbursement variation. Japan and other Asian markets contribute additional volume but may have narrower reimbursement criteria.

Patent and generic entry are jurisdiction-specific. A U.S. generic launch would not automatically produce simultaneous entry in Europe, Japan or other markets.

What generic launch scenarios exist for midostaurin?

Three scenarios are commercially relevant.

Scenario 1: Delayed generic entry

Patent litigation or formulation barriers delay launch until the late 2020s or around 2030. Rydapt maintains a stable revenue base, but quizartinib and avapritinib limit growth.

Scenario 2: At-risk launch

A generic manufacturer launches before final resolution of patent litigation. This could produce rapid price erosion and a sharp decline in U.S. revenue if the product is later found to infringe.

Scenario 3: Limited-label generic entry

A generic launches with patented indications carved out. The product may compete in selected uses, while Novartis retains some protected indication share. This outcome could slow, rather than eliminate, Rydapt erosion.

For a mature product with approximately $0.5 billion in global sales, the United States would likely account for a disproportionate share of early revenue loss because of pricing and generic substitution mechanics.

How does Rydapt compare with Ayvakit and Vanflyta commercially?

Rydapt has the advantage of market tenure and established clinical use. Ayvakit and Vanflyta have more recent mechanisms and can target segments where Rydapt is less differentiated.

Commercial factor Rydapt Ayvakit Vanflyta
Core disease area AML and advanced systemic mastocytosis Systemic mastocytosis FLT3-ITD-positive AML
Launch maturity Mature Growth-stage Growth-stage
Key advantage Established front-line AML use Selective KIT targeting and broader mastocytosis opportunity Direct front-line FLT3-ITD competition
Main risk Patent and generic erosion Safety, reimbursement and market development Narrower mutation coverage and adoption barriers
Revenue profile Stable mature product Expansion-oriented Newer launch with competitive pressure

Rydapt’s strongest defense is its entrenched role in FLT3-mutated AML treatment. Its weakest position is systemic mastocytosis, where avapritinib offers a more targeted competitor and may capture treatment share as diagnosis expands.

Key Takeaways

  • Midostaurin is a mature specialty oncology product with global annual sales near $0.5 billion.
  • Rydapt revenue is supported by front-line FLT3-mutated AML and advanced systemic mastocytosis.
  • The AML business is durable but faces direct pressure from quizartinib and indirect pressure from gilteritinib.
  • Avapritinib is the main competitive threat in systemic mastocytosis.
  • The seven-year orphan exclusivity periods from the 2017 approvals have generally expired.
  • Rydapt is exposed to generic, not biosimilar, competition.
  • Later patents and method-of-use claims may delay U.S. generic entry into the late 2020s or around 2030.
  • No cited public source establishes a definitive Rydapt generic launch date or settlement-based entry date.
  • Revenue is likely to remain stable before generic entry, with limited growth potential.
  • A successful paragraph IV challenge would create the largest near-term valuation risk.

FAQs About Midostaurin Market Dynamics

Is midostaurin still a standard treatment for FLT3-mutated AML?

Yes. Midostaurin remains an approved front-line option for newly diagnosed FLT3-mutated AML when used with intensive induction and consolidation chemotherapy.

Does midostaurin have biosimilar competition?

No. Midostaurin is a small-molecule drug, so any future competition would come from generic versions rather than biosimilars.

Which drug competes most directly with Rydapt in AML?

Quizartinib is the most direct newer competitor in newly diagnosed FLT3-ITD-positive AML. Gilteritinib competes more strongly in relapsed or refractory FLT3-mutated AML.

Which drug competes most directly with Rydapt in systemic mastocytosis?

Avapritinib is the principal direct competitor, particularly because of its selective KIT activity and systemic mastocytosis indications.

What would cause Rydapt sales to decline sharply?

The most likely causes are an approved generic, an at-risk generic launch, loss of front-line AML share to quizartinib, or accelerated displacement in systemic mastocytosis by avapritinib.

References

  1. Food and Drug Administration. (2023). FDA approves quizartinib with chemotherapy for newly diagnosed acute myeloid leukemia. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  3. Food and Drug Administration. (2017). Rydapt prescribing information. U.S. Department of Health and Human Services.

  4. Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., et al. (2016). Efficacy and safety of midostaurin in advanced systemic mastocytosis. New England Journal of Medicine, 374(26), 2530-2541.

  5. Novartis. (2021). Annual report 2021. Novartis AG.

  6. Novartis. (2022). Annual report 2022. Novartis AG.

  7. Novartis. (2023). Annual report 2023. Novartis AG.

  8. Novartis. (2024). Annual report 2024. Novartis AG.

  9. Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., et al. (2017). Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, 377(5), 454-464.

  10. United States Patent and Trademark Office. (2024). Patent Center and patent term information. U.S. Department of Commerce.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.